3rd Future of PV 2026

Alwis: At Alwis Group, we’re pioneering AI-driven solutions for the healthcare and pharmaceutical industries. Our innovative tools are transforming pharmacovigilance, enhancing drug safety monitoring, and streamlining regulatory compliance. Our suite of products includes: 

• ReTrans Enterprise: AI-powered literature surveillance 

• ReTrans Extension: Browser plugin for real-time safety data analysis 

• ScoMed: Intelligent medical literature scoring * ZiNex: Advanced medical document processing 

• ZiQuel: AI-driven quality complaint management 

• ZiTrack: Smart inbound receipt management 

We’re committed to improving patient safety and operational efficiency through cutting-edge technology. Our solutions reduce costs, minimize errors, and accelerate processes, allowing healthcare professionals to focus on what matters most – patient care.

At Ultragenic, we’re committed to advancing patient outcomes through innovative solutions that address the challenges and opportunities across the Pharmacovigilance function. We combine domain expertise in life sciences, third-party system knowledge, and advanced technology to develop agile, flexible, and scalable solutions that free up responsible personnel within Pharma companies to execute their responsibilities while staying compliant with regulations and managing business risks. Our core team has over two decades of experience in engineering and deploying best-in-class life sciences solutions. They bring a unique blend of technical, business, and regulatory expertise with a track record of scaling operations globally.

ArcaScience builds the first AI platform dedicated to benefit–risk assessment, streamlining work that used to take months into minutes. It delivers 10 to 100× more relevant, traceable insights, enabling pharmacovigilance teams to understand and act on the benefit–risk balance with confidence.

Biologit delivers advanced active safety surveillance solutions for the life sciences sector, addressing human and veterinary pharmacovigilance, cosmetovigilance, nutravigilance, and materiovigilance. Biologit MLM-AI is a state-of-the-art platform for monitoring scientific literature to identify adverse events and emerging risks throughout a product’s lifecycle, from clinical development to post-marketing. Designed for teams of all sizes, it combines a flexible workflow with a unified global and local scientific database, enhanced by unique AI-driven screening and productivity tools. These features enable fast, accurate, and fully traceable results for all safety surveillance needs. Biologit Database is a robust, continuously updated repository of scientific literature, optimised for compliant regulatory searches. It integrates global and regional sources into an intuitive interface, delivering high-quality results for monitoring adverse events and potential risks. With over 65 million entries and 40,000 new articles added daily from 120,000 journals across 170+ countries, it ensures comprehensive coverage aligned with FDA, EMA GVP and global standards. Biologit provides a full suite of pharmacovigilance services, including Qualified Person for Pharmacovigilance (QPPV) and Responsible Person for Pharmacovigilance (RPPV) support in clinical trials.

Synapmed is a science-led, AI-native, full-service CRO transforming drug safety, compliance, and clinical development across the product lifecycle. The organization supports programs from pre-clinical through post-marketing across 40+ countries, operating in 60+ languages, and spanning ten plus therapeutic and rare-disease areas. With ISO-certified quality systems and a unified, inspection-ready operating model, Synapmed integrates clinical operations, regulatory affairs, pharmacovigilance, medical affairs, real-world evidence, and market access within a single connected platform, ensuring end-to-end traceability, auditability, and regulatory compliance across all deliverables. In parallel, Synapmed is pioneering the future of medical AI by contributing real-world, high-impact use cases to the training of one of the world’s most advanced large language models. We have recently supported a top-20 global pharmaceutical company in analyzing data from 50,000+ patients across 11 rare diseases, using AI to uncover treatment and biomarker patterns and enable up to 60% faster, data-driven decision-making.